# A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

> **NCT06317311** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 41 (actual)

## Conditions studied

- Carcinoma

## Interventions

- **BIOLOGICAL:** Dostarlimab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06317311
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-07
- **Primary completion:** 2026-07-15
- **Final completion:** 2027-08-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06317311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06317311, "A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06317311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*